Key result
HbA1c >=5.45% in non-diabetics is linked to ~2.2-fold higher risk of CAD.
Why the study?
Current knowledge suggests a relationship between glycated hemoglobin (HbA1c) and cardiovascular diseases in non-diabetics, prompting evaluation of the predictive value of HbA1c for cardiovascular diseases in this population.
Does an elevated HbA1c (>=5.45%) increase the odds of coronary heart disease and other macrovascular complications in non-diabetic patients?
Cross-Sectional (n=77)
No
Does an elevated HbA1c (>=5.45%) increase the odds of coronary heart disease and other macrovascular complications in non-diabetic patients?
Answers are grounded in this paper and cite their sources.
In non-diabetic individuals, an HbA1c level of 5.45% or higher is significantly associated with more than double the odds of coronary heart disease, supporting its potential utility as a cardiovascular risk biomarker even in the absence of diabetes.
Cardiovascular diseases are a major cause of morbidity and mortality. Current knowledge suggests that there is a relationship between glycated hemoglobin (HbA1c) and cardiovascular diseases, also in non-diabetics. Glycated hemoglobin (HbA1c) is a laboratory indicator that reflects the average blood sugar level over the past two to three months. Statistical methods. We determined monitored parameter: glycated hemoglobin. We determined the mentioned disease states. We expressed the relationship as a ratio of chances (Odds ratio, OR) (Mikulecký, M. 2003). The results of our work showed that non-diabetics who have an HbA1c value of 5.45 and higher have an risk of coronary heart disease 2.171 times higher compared to non-diabetics who have an HbA1c lower than 5.45 (OR=2.171) (95 % IS 1.095 – 4.304), the influence of the presence of HbA1c on the occurrence of coronary heart disease is statistically significant in this case (p ≤ 0.05). In non-diabetics, we demonstrated the effect of HbA1c on the development of the disease even in the case of the risk of myocardial infarction, stroke, peripheral arterial disease of the lower limbs, the results were statistically non-significant. Further studies are needed to clarify the relationship between HbA1c and cardiovascular diseases in non-diabetics.
No takes yet. Share an insight, caveat, or question.
Daňová et al. (2026) conducted a cross-sectional in Cardiovascular diseases in non-diabetics (n=77). Glycated hemoglobin (HbA1c) >= 5.45% vs. Glycated hemoglobin (HbA1c) < 5.45% was evaluated on Coronary artery disease (coronary heart disease) (OR 2.171, 95% CI 1.095-4.304, p=≤0.05). HbA1c >=5.45% in non-diabetics was associated with a 2.171 times higher risk of coronary heart disease compared to HbA1c <5.45%.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: